SWTX — SpringWorks Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $3.35bn
- $3.05bn
- $191.59m
Annual income statement for SpringWorks Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 35 | 0 | 0 | 5.45 | 192 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 5.03 | 179 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 81.3 | 173 | 281 | 348 | 470 |
| Operating Profit | -46.3 | -173 | -281 | -343 | -278 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -45.6 | -174 | -277 | -325 | -258 |
| Net Income After Taxes | -45.6 | -174 | -277 | -325 | -258 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -45.6 | -174 | -277 | -325 | -258 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -45.6 | -174 | -277 | -325 | -258 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.05 | -3.59 | -5.21 | -5.15 | -3.48 |